Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Depemokimab - GSK

Next Previous
X
Search
Drug Profile

Depemokimab - GSK

Alternative Names: AQ82742999; GSK 294; GSK-3511294

Latest Information Update: 23 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Asthma; Churg-Strauss syndrome; Hypereosinophilic syndrome; Rhinosinusitis

Most Recent Events

  • 11 Apr 2024 GlaxoSmithKline completes the phase III SWIFT-2 trial in Asthma (In adolescents, In adults, In children, In the elderly, Adjunctive treatment) in USA, Australia, Canada, Czech Republic, France, Hungary, Italy, Japan, Poland, Spain, Taiwan (Injection), after February 2021 (NCT04718103)
  • 21 Nov 2023 GlaxoSmithKline completes a phase III SWIFT 1 trial in Asthma (In adolescents, In adults, In children, In the elderly, Adjunctive treatment) the US, Canada, China, Czechia, France, Germany, Ireland, Italy, Poland, Russia, Spain and the United Kingdom (NCT04719832) (EudraCT2020-003632-25; 206713)
  • 23 Oct 2023 GlaxoSmithKline completes a phase I pharmacokinetics trial for Asthma (In volunteers) (SC, Injection) (NCT05602025)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top